Frequency and severity of solicited local and systemic adverse events (AE);Immune response measured after completion of a 2-dose immunization schedule with VLA2001 as determined by seroconversion rate (SCR) (defined as 4-fold increase from baseline) of SARS-CoV-2-specific neutralising antibodies;Immune respsonse measured after completion of a 2-dose immunization schedule with VLA2001 as determined by the Geometric Mean Titer (GMT)

Frequency and severity of solicited local and systemic adverse events (AE);Immune response measured after completion of a 2-dose immunization schedule with VLA2001 as determined by seroconversion rate (SCR) (defined as 4-fold increase from baseline) of SARS-CoV-2-specific neutralising antibodies;Immune respsonse measured after completion of a 2-dose immunization schedule with VLA2001 as determined by the Geometric Mean Titer (GMT)